Literature DB >> 21911495

Dual conformation of H2H3 domain of prion protein in mammalian cells.

Zhou Xu1, Stéphanie Prigent, Jean-Philippe Deslys, Human Rezaei.   

Abstract

The concept of prion is applied to protein modules that share the ability to switch between at least two conformational states and transmit one of these through intermolecular interaction and change of conformation. Although much progress has been achieved through the understanding of prions from organisms such as Saccharomyces cerevisiae, Podospora anserina, or Aplysia californica, the criteria that qualify a protein module as a prion are still unclear. In addition, the functionality of known prion domains fails to provide clues to understand the first identified prion, the mammalian infectious prion protein, PrP. To address these issues, we generated mammalian cellular models of expression of the C-terminal two helices of PrP, H2 and H3, which have been hypothesized, among other models, to hold the replication and conversion properties of the infectious PrP. We found that the H2H3 domain is an independent folding unit that undergoes glycosylations and glycosylphosphatidylinositol anchoring similar to full-length PrP. Surprisingly, in some conditions the normally folded H2H3 was able to systematically go through a conversion process and generate insoluble proteinase K-resistant aggregates. This structural switch involves the assembly of amyloid structures that bind thioflavin S and oligomers that are reactive to A11 antibody, which specifically detects protein oligomers from neurological disorders. Overall, we show that H2H3 is a conformational switch in a cellular context and is thus suggested to be a candidate for the conversion domain of PrP.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21911495      PMCID: PMC3220554          DOI: 10.1074/jbc.M111.275255

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  42 in total

1.  Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis.

Authors:  Rakez Kayed; Elizabeth Head; Jennifer L Thompson; Theresa M McIntire; Saskia C Milton; Carl W Cotman; Charles G Glabe
Journal:  Science       Date:  2003-04-18       Impact factor: 47.728

Review 2.  Prions as protein-based genetic elements.

Authors:  Susan M Uptain; Susan Lindquist
Journal:  Annu Rev Microbiol       Date:  2002-01-30       Impact factor: 15.500

3.  Reiterating the epitope specificity of prion-specific mAb 3F4.

Authors:  Richard Kascsak
Journal:  J Biol Chem       Date:  2010-05-14       Impact factor: 5.157

4.  The protein product of the het-s heterokaryon incompatibility gene of the fungus Podospora anserina behaves as a prion analog.

Authors:  V Coustou; C Deleu; S Saupe; J Begueret
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

5.  Separation and properties of cellular and scrapie prion proteins.

Authors:  R K Meyer; M P McKinley; K A Bowman; M B Braunfeld; R A Barry; S B Prusiner
Journal:  Proc Natl Acad Sci U S A       Date:  1986-04       Impact factor: 11.205

6.  Development and characterization of clonal cell lines derived from septal cholinergic neurons.

Authors:  D N Hammond; H J Lee; J H Tonsgard; B H Wainer
Journal:  Brain Res       Date:  1990-04-02       Impact factor: 3.252

7.  Mouse polyclonal and monoclonal antibody to scrapie-associated fibril proteins.

Authors:  R J Kascsak; R Rubenstein; P A Merz; M Tonna-DeMasi; R Fersko; R I Carp; H M Wisniewski; H Diringer
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

8.  Mechanistic insights into cellular alteration of prion by poly-D-lysine: the role of H2H3 domain.

Authors:  Zhou Xu; Miquel Adrover; Annalisa Pastore; Stéphanie Prigent; Franck Mouthon; Emmanuel Comoy; Human Rezaei; Jean-Philippe Deslys
Journal:  FASEB J       Date:  2011-06-22       Impact factor: 5.191

9.  Truncated forms of the human prion protein in normal brain and in prion diseases.

Authors:  S G Chen; D B Teplow; P Parchi; J K Teller; P Gambetti; L Autilio-Gambetti
Journal:  J Biol Chem       Date:  1995-08-11       Impact factor: 5.157

10.  GPI anchoring facilitates propagation and spread of misfolded Sup35 aggregates in mammalian cells.

Authors:  Jonathan O Speare; Danielle K Offerdahl; Aaron Hasenkrug; Aaron B Carmody; Gerald S Baron
Journal:  EMBO J       Date:  2010-01-07       Impact factor: 11.598

View more
  6 in total

1.  A novel mutation I215V in the PRNP gene associated with Creutzfeldt-Jakob and Alzheimer's diseases in three patients with divergent clinical phenotypes.

Authors:  Mercedes Muñoz-Nieto; Neus Ramonet; Juan Ignacio López-Gastón; Natividad Cuadrado-Corrales; Olga Calero; Marcos Díaz-Hurtado; José Ramón Ipiens; Santiago Ramón y Cajal; Jesús de Pedro-Cuesta; Miguel Calero
Journal:  J Neurol       Date:  2012-07-05       Impact factor: 4.849

2.  Critical significance of the region between Helix 1 and 2 for efficient dominant-negative inhibition by conversion-incompetent prion protein.

Authors:  Yuzuru Taguchi; Arla M A Mistica; Tetsuyuki Kitamoto; Hermann M Schätzl
Journal:  PLoS Pathog       Date:  2013-06-27       Impact factor: 6.823

Review 3.  Biochemical insight into the prion protein family.

Authors:  Danica Ciric; Human Rezaei
Journal:  Front Cell Dev Biol       Date:  2015-02-11

4.  How does domain replacement affect fibril formation of the rabbit/human prion proteins.

Authors:  Xu Yan; Jun-Jie Huang; Zheng Zhou; Jie Chen; Yi Liang
Journal:  PLoS One       Date:  2014-11-17       Impact factor: 3.240

5.  Two misfolding routes for the prion protein around pH 4.5.

Authors:  Julian Garrec; Ivano Tavernelli; Ursula Rothlisberger
Journal:  PLoS Comput Biol       Date:  2013-05-16       Impact factor: 4.475

6.  Decrypting Prion Protein Conversion into a β-Rich Conformer by Molecular Dynamics.

Authors:  Nesrine Chakroun; Arianna Fornili; Stéphanie Prigent; Jens Kleinjung; Cécile A Dreiss; Human Rezaei; Franca Fraternali
Journal:  J Chem Theory Comput       Date:  2013-04-04       Impact factor: 6.006

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.